Findings from the phase 3 ADAPT SERON trial demonstrated that efgartigimod IV significantly improved MG-ADL total scores in patients who were acetylcholine receptor antibody seronegative. The Food and ...

For adults with severe scabies, higher-dose ivermectin plus permethrin is not superior to standard-dose ivermectin plus permethrin, according to a study published in the May 7 issue of the New England ...

Replacing universal vaccination with targeted birth-dose vaccine recommendation likely to result in increase in infections ...

Bariatric surgery rates rose gradually while GLP-1 receptor agonist prescriptions grew exponentially from 2018 to 2025.

Treatments for COVID-19, gout, nicotine dependence, severe hypertriglyceridemia, and thyroid eye disease are under review.

The newly approved oral formulation features a smaller pill size in 1.5mg, 4mg, and 9mg strengths while maintaining the efficacy and safety profile of the previous oral semaglutide version.

Topline data from the ACACIA-HCM study reveal that the cardiac myosin inhibitor aficamten met all primary and key secondary endpoints, offering a potential new treatment pathway for patients with ...

Tazbentetol is an investigational, once-daily synaptic regenerative therapy designed to restore cognitive and motor function in ALS.

Based on the current evidence, there is no consistent association between vaccines and serious or long-term health outcomes.

Ozempic tablets are now available; investigational ALS treatment gains FDA Fast Track status; positive results for aficamten ...

However, most patients report preferring LAI-ART administered monthly or once every 2 months vs daily oral ART.

A larger percentage of patients in PFA group had treatment success at 12 months compared with those receiving antiarrhythmic-drug therapy.